The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts).
Yves Boucher
No relevant relationships to disclose
John D. Martin
No relevant relationships to disclose
Sara M. Tolaney
Research Funding - Genentech
Marek Ancukiewicz
No relevant relationships to disclose
Giorgio Seano
No relevant relationships to disclose
Shom Goel
No relevant relationships to disclose
Eren Yeh
No relevant relationships to disclose
Jack E Meyer
No relevant relationships to disclose
Steven J. Isakoff
No relevant relationships to disclose
Dan G. Duda
No relevant relationships to disclose
Eric P. Winer
No relevant relationships to disclose
Ian E. Krop
Research Funding - Genentech
Rakesh K. Jain
Employment or Leadership Position - H&Q Healthcare Investors; H&Q Life Sciences Investors; XTuit Pharmaceuticals
Consultant or Advisory Role - Dyax; Enlight Biosciences; Noxxon Pharma; SynDevRx; Zyngenia
Stock Ownership - Enlight Biosciences; SynDevRx; XTuit Pharmaceuticals
Research Funding - Dyax; MedImmune; Roche